Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes through innovative research and clinical development.

The flagship investigational product is a precision medicine treatment under clinical evaluation, serving as a disease-modifying therapy aimed at preserving endogenous insulin production in individuals with type 1 diabetes. It is based on the autoantigen GAD65 and has received Orphan Drug Designation as well as Fast Track Designation by the U.S. FDA.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.